Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Structural Basis of Vitamin K Antagonism

Weikai Li, PhD, Shixuan Liu, Shuang Li

Blood (2019) 134 (Supplement_1): 482.

https://doi.org/10.1182/blood-2019-127324

Published: 2019

Journal Articles

PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation

Martin K. Safo, PhD, Piyusha P Pagare, PhD, Mohini Ghatge, PhD, Carla Casu, PhD, Valentina Ghiaccio, PhD, Nancy Anabaraonye, Xiaomeng Xu, MS, Stefano Rivella, PhD, Patrick C. Hines, MD PhD, Ke Liu, PhD, Yan Zhang, PhD, Jürgen Venitz, MD PhD, Osheiza Abdulmalik, DVM

Blood (2019) 134 (Supplement_1): 73.

https://doi.org/10.1182/blood-2019-128646

Published: 2019

Journal Articles

Busulfan Pharmacogenetics and Drug Exposure in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation

Jai N Patel, PharmD, Issam Hamadeh, BS, Qing Zhang, PhD, Taylor Brown, BS, MS, Nury M Steuerwald, PhD, Alicia Hamilton, Lawrence J Druhan, PhD, Jiaxian He, MS, James T Symanowski, PhD, Mohammed J Hussain, MD, Jigar Trivedi, MSc, PharmD, Michael Richard Grunwald, MD, Nilanjan Ghosh, MD PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD

Blood (2017) 130 (Supplement 1): 3215.

https://doi.org/10.1182/blood.V130.Suppl_1.3215.3215

Published: 2017

Journal Articles

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

Alexander V Lavrov, MD PhD, Oksana A Ustaeva, Elmira P Adilgereeva, Svetlana A Smirnikhina, Ekaterina Chelysheva, MD, Oleg Shukhov, MD, Yuriy V Shatokhin, Sergey V Mordanov, Anna G Turkina, Prof., MD, Sergey Kutsev

Blood (2016) 128 (22): 5457.

https://doi.org/10.1182/blood.V128.22.5457.5457

Published: 2016

Journal Articles

Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?

Philip S Wells, MD, Michael J. Kovacs, MD FRCPC, David Anderson, MD, Susan R. Kahn, MD, Clive Kearon, MB, Sam Schulman, MD PhD FRCPC, David M. Keeling, MD, Scott Kaatz, DO, MSc, Susan Solymoss, MD, Daniel J Corsi, PhD, Marc Rodger, MD MSc, FRCPC

Blood (2016) 128 (22): 272.

https://doi.org/10.1182/blood.V128.22.272.272

Published: 2016

Journal Articles

Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study

Blood (2015) 126 (23): 2483.

https://doi.org/10.1182/blood.V126.23.2483.2483

Published: 2015

Journal Articles

Race influences warfarin dose changes associated with genetic factors

Nita A. Limdi, Todd M. Brown, Qi Yan, Jonathan L. Thigpen, Aditi Shendre, Nianjun Liu, Charles E. Hill, Donna K. Arnett, T. Mark Beasley

Blood (2015) 126 (4): 539–545.

https://doi.org/10.1182/blood-2015-02-627042

Published: 2015

Journal Articles

Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group

Blood (2014) 124 (21): 424.

https://doi.org/10.1182/blood.V124.21.424.424

Published: 2014

Journal Articles

Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans

Roxana Daneshjou, Eric R. Gamazon, Ben Burkley, Larisa H. Cavallari, Julie A. Johnson, Teri E. Klein, Nita Limdi, Sara Hillenmeyer, Bethany Percha, Konrad J. Karczewski, Taimour Langaee, Shitalben R. Patel, Carlos D. Bustamante, Russ B. Altman, Minoli A. Perera

Blood (2014) 124 (14): 2298–2305.

https://doi.org/10.1182/blood-2014-04-568436

Published: 2014

Includes: Supplemental data

Journal Articles

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Athiwat Hutchaleelaha, Ph.D., Christine Ye, Ph.D., Yonghong Song, Ph.D., Todd Lorenz, MD, Daniel Gretler, MD, Joseph L Lambing, Ph.D.

Blood (2012) 120 (21): 2266.

https://doi.org/10.1182/blood.V120.21.2266.2266

Published: 2012

Journal Articles

Different Panel of Gene Variants Influence Outcome of Transplant From Sibling Donors Compared to HLA-Identical Unrelated Donors

Ahmet H Elmaagacli, MD, PhD, Michael Koldehoff, MD, Nina Kristin Steckel, Markus Ditschkowski, Rudolf Trenschel, MD, Hellmut Ottinger, Dietrich W. Beelen, MD

Blood (2012) 120 (21): 4182.

https://doi.org/10.1182/blood.V120.21.4182.4182

Published: 2012

Journal Articles

Polymorphisms in VKORC1, CYP2C9, and CYP4F2 and Warfarin Dose in the Pediatric Population

Susan I. Vear, MD, Gregory D. Ayers, MS, C. Michael Stein, MD, MBChB, Richard H. Ho, MD, MSCI

Blood (2012) 120 (21): 4358.

https://doi.org/10.1182/blood.V120.21.4358.4358

Published: 2012

Journal Articles

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement

Caroline Moreau, Fanny Bajolle, Virginie Siguret, Dominique Lasne, Jean-Louis Golmard, Caroline Elie, Philippe Beaune, Radhia Cheurfi, Damien Bonnet, Marie-Anne Loriot

Blood (2012) 119 (3): 861–867.

https://doi.org/10.1182/blood-2011-07-365502

Published: 2012

Includes: Supplemental data

Journal Articles

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children

Tina T. Biss, Peter J. Avery, Leonardo R. Brandão, Elizabeth A. Chalmers, Michael D. Williams, John D. Grainger, Julian B. S. Leathart, John P. Hanley, Ann K. Daly, Farhad Kamali

Blood (2012) 119 (3): 868–873.

https://doi.org/10.1182/blood-2011-08-372722

Published: 2012

Journal Articles

Results of Simultaneously Performed Analysis of 48 Gene Variants Reported to Have Influence on Transplant outcome

Ahmet Elmaagacli, MD, Michael Koldehoff, MD, Nina Steckel, Hellmut Ottinger, Dietrich Beelen

Blood (2011) 118 (21): 3047.

https://doi.org/10.1182/blood.V118.21.3047.3047

Published: 2011

Journal Articles

The VKORC1 and CYP2C9 Genotypes Significantly Affect Vitamin K Antagonist Dosing Only in Patients Aged 20 Years or Older

Ulrike Nowak-Gottl, MD, Kevin Dietrich, Andre Franke, Noha Sharaf El-Din, Yutaka Yasui, Lesley G Mitchell

Blood (2011) 118 (21): 1243.

https://doi.org/10.1182/blood.V118.21.1243.1243

Published: 2011

Journal Articles

Warfarin Untargeted Metabolomics Study Identifies Novel Procoagulant Ethanolamide Lipids

Hiroshi Deguchi, MD, PhD, Sunia Trauger, PhD, Ewa Kalisiak, PhD, Hui-Min Zhang, PhD, Gary Siuzdak, PhD, John H. Griffin, PhD, Darlene J Elias, MD

Blood (2011) 118 (21): 1200.

https://doi.org/10.1182/blood.V118.21.1200.1200

Published: 2011

Journal Articles

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy

Inna Y. Gong, Rommel G. Tirona, Ute I. Schwarz, Natalie Crown, George K. Dresser, Samantha LaRue, Nicole Langlois, Alejandro Lazo-Langner, Guangyong Zou, Dan M. Roden, C. Michael Stein, Marc Rodger, Marc Carrier, Melissa Forgie, Philip S. Wells, Richard B. Kim

Blood (2011) 118 (11): 3163–3171.

https://doi.org/10.1182/blood-2011-03-345173

Published: 2011

Includes: Supplemental data

Journal Articles

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes

Ulrike Nowak-Göttl, Kevin Dietrich, Daria Schaffranek, Noha Sharaf Eldin, Yutaka Yasui, Christof Geisen, Lesley G. Mitchell

Blood (2010) 116 (26): 6101–6105.

https://doi.org/10.1182/blood-2010-05-283861

Published: 2010

Includes: Supplemental data

Journal Articles

Does VKORC1 and CYP2C9 Genotyping Help to Predict the Maintenance Dose In Elderly Inpatients at Warfarin Treatment Initiation?

Caroline Moreau, Eric Pautas, Isabelle Gouin-Thibault, Jean-Louis Golmard, Marie-Anne Loriot, Virginie Siguret

Blood (2010) 116 (21): 189.

https://doi.org/10.1182/blood.V116.21.189.189

Published: 2010

NARROW

Structural Basis of Vitamin K Antagonism

PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation

Busulfan Pharmacogenetics and Drug Exposure in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?

Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study

Race influences warfarin dose changes associated with genetic factors

Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group

Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Different Panel of Gene Variants Influence Outcome of Transplant From Sibling Donors Compared to HLA-Identical Unrelated Donors

Polymorphisms in VKORC1, CYP2C9, and CYP4F2 and Warfarin Dose in the Pediatric Population

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children

Results of Simultaneously Performed Analysis of 48 Gene Variants Reported to Have Influence on Transplant outcome

The VKORC1 and CYP2C9 Genotypes Significantly Affect Vitamin K Antagonist Dosing Only in Patients Aged 20 Years or Older

Warfarin Untargeted Metabolomics Study Identifies Novel Procoagulant Ethanolamide Lipids

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes

Does VKORC1 and CYP2C9 Genotyping Help to Predict the Maintenance Dose In Elderly Inpatients at Warfarin Treatment Initiation?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only